Company / Cash & Equivalents
CorMedix Inc. Cash & Equivalents History
FY2016-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest Cash & Equivalents
$144.8M
FY2025
5-year range
$40.7M / $144.8M
FY2021-FY2025
Trend
+256.3%
vs FY2024
Sector context
Sector data unavailable
Latest sector comparison
What the data says
Cash & Equivalents changed +256% YoY in FY2025, a notable deviation from the 9-year average annual change of +52%.
Based on SEC 10-K filings.
$145M in FY2025 with a 5-year CAGR of +28.2%.
Improved from $44M to $145M over the past 2 years.
Cash & Equivalents over time
Growth rates
- 3-Year CAGR
- +49.7%
- 5-Year CAGR
- +28.2%
- 10-Year CAGR
- -
Key checks
Key Insights
- 5-year CAGR of +28.2%, indicating consistent growth.
- In FY2025, cash & equivalents increased 256.3% year-over-year.
- Lowest cash & equivalents in the period was in FY2017.
Annual data
| Year | Cash & EquivalentsValue | YoY GrowthYoY |
|---|---|---|
| FY2025 | $144.8M | +256.3% |
| FY2024 | $40.7M | -6.9% |
| FY2023 | $43.6M | +1.1% |
| FY2022 | $43.1M | -19.1% |
| FY2021 | $53.3M | +27.2% |
| FY2020 | $41.9M | +156.3% |
| FY2019 | $16.4M | -7.2% |
| FY2018 | $17.6M | +69.8% |
| FY2017 | $10.4M | -12.2% |
| FY2016 | $11.8M | +0.0% |
As of FY2025 · SEC 10-K · Updated Jun 24, 2026